Vizen Life Sciences Pvt Ltd Hiring For Drug Safety Associate - ICSR
Position Name: Drug Safety Associate - ICSR
Organization: Vizen Life Sciences Pvt Ltd
Qualification: B Pharm, M Pharm, Pharm D
Experience: 1-6 Years
Salary: ₹4,00,000 - ₹8,00,000 Per Annum
Location: Hyderabad, Telangana, India
Email: careers@vizenlifesciences.com
Responsibilities
- Collect, review, and enter Individual Case Safety Reports (ICSRs) from multiple sources including healthcare professionals, patients, and literature into the Argus Safety database.
- Perform initial case assessment to determine seriousness, expectedness, and causality of adverse events.
- Ensure completeness and accuracy of all data fields in accordance with regulatory guidelines (ICH E2B(R3), FDA, EMA).
- Conduct follow‑up activities with reporters to obtain missing or additional information for incomplete cases.
- Prepare and submit expedited safety reports (e.g., SUSARs, DSURs) to global regulatory authorities within stipulated timelines.
- Maintain and update safety data management SOPs, work instructions, and training materials.
- Participate in signal detection activities by reviewing aggregated safety data and generating safety narratives.
- Collaborate with cross‑functional teams (clinical, medical affairs, regulatory) to resolve safety queries and provide risk assessments.
- Assist in the preparation of periodic safety update reports (PSURs) and risk management plans (RMPs).
- Perform data quality checks, validation, and reconciliation of safety data across multiple systems.
- Support the preparation of safety sections for clinical trial protocols, investigator brochures, and product labeling.
- Monitor and evaluate safety literature, including scientific journals and databases, for relevant adverse event information.
- Coordinate with external vendors and contract research organizations (CROs) for safety data collection and management.
- Ensure compliance with internal audit findings and external regulatory inspections related to pharmacovigilance activities.
- Provide training and mentorship to junior pharmacovigilance staff on case processing and regulatory requirements.
- Generate safety metrics and key performance indicators (KPIs) for management reporting.
- Participate in risk communication activities, including preparation of safety bulletins and newsletters.
- Assist in the development and implementation of pharmacovigilance risk assessment tools.
- Maintain up‑to‑date knowledge of global pharmacovigilance regulations and industry best practices.
- Support the preparation of safety data for product launches and post‑marketing surveillance plans.
- Conduct root cause analysis for data discrepancies and implement corrective actions.
- Prepare and review safety data for regulatory submissions such as NDAs, BLAs, and MAAs.
- Facilitate communication with health authorities during safety signal investigations.
- Assist in the management of safety databases, ensuring data integrity and security.
- Participate in internal and external pharmacovigilance audits and implement corrective action plans.
- Develop and maintain safety documentation, including case narratives, aggregate reports, and safety summaries.
- Support the execution of pharmacovigilance training programs for internal stakeholders.
- Collaborate with IT teams to enhance safety data capture tools and workflow automation.
- Prepare ad‑hoc safety analyses and presentations for senior management and cross‑functional meetings.
- Ensure timely and accurate reporting of adverse events in accordance with local and global timelines.
Skills
- Pharmacovigilance case processing
- Argus Safety (Oracle) expertise
- ICH E2B(R3) guidelines
- FDA 21 CFR Part 312 compliance
- EMA GVP regulations
- Adverse event causality assessment
- Medical terminology (MedDRA, WHO-ART)
- Data entry accuracy and validation
- Signal detection and data mining
- Risk management plan development
- Regulatory submission preparation
- Scientific literature review
- Effective communication with healthcare professionals
- Time‑critical reporting (SUSAR, DSUR)
- Root cause analysis and corrective actions
- Cross‑functional collaboration
- Project management and prioritization
- Attention to detail and analytical thinking
- Knowledge of clinical trial phases
- Understanding of drug development lifecycle
- Proficiency in Microsoft Office Suite
- Quality assurance and audit readiness
- Vendor management and CRO coordination
- Training and mentorship abilities
- Problem‑solving and decision‑making
- Ethical handling of patient data
- Regulatory intelligence gathering
- Preparation of safety narratives
- KPI tracking and reporting
- Continuous improvement mindset
Company Overview
Vizen Life Sciences Pvt Ltd is a fast‑growing, innovation‑driven pharmaceutical company headquartered in Hyderabad, India. Specializing in drug development, contract research, and advanced pharmacovigilance services, Vizen delivers end‑to‑end solutions across the life sciences spectrum. The company’s portfolio includes generic medicines, specialty formulations, and cutting‑edge biologics that serve both domestic and international markets. With a robust presence in over 30 countries, Vizen is recognized for its commitment to quality, regulatory excellence, and patient safety. Employees benefit from a dynamic career growth environment, continuous learning programs, and exposure to global regulatory standards. Vizen’s reputation for scientific rigor, ethical practices, and collaborative culture makes it an attractive destination for aspiring pharma professionals seeking impactful roles in drug safety and beyond.
#PharmaJobs #Hiring #ClinicalResearch #RegulatoryAffairs #HealthcareCareers
Apply For Job
Your safety comes first. We collect job postings from multiple public sources (company sites, LinkedIn, Google Jobs, WhatsApp/Telegram groups, etc.). Never pay money or share bank/OTP details to get a job — genuine recruiters don't ask for that.
Source Reference
Share this Job:
Common Interview Questions for Drug Safety Associate - ICSR
Prepare for your interview by reviewing these frequently asked questions. Click on a question to reveal the answer.
What are the key components of an Individual Case Safety Report (ICSR) and why are they important?
An ICSR must include patient demographics, suspect drug information, adverse event description, seriousness criteria, outcome, and reporter details. These components ensure accurate causality assessment, regulatory compliance, and enable timely signal detection, which are critical for patient safety and meeting global pharmacovigilance obligations.
Explain the process of causality assessment for an adverse event.
Causality assessment involves evaluating temporal relationship, de‑challenge/re‑challenge information, alternative causes, and known drug safety profile. Methods such as WHO‑UMC or Naranjo algorithm are applied to assign a likelihood category (certain, probable, possible, unlikely, unrelated). This systematic approach supports regulatory reporting and risk management decisions.
How do you ensure data quality when entering cases into Argus Safety?
Data quality is maintained by following SOPs, performing double‑checks, using validation rules, and conducting periodic audits. I verify source documents, cross‑reference MedDRA coding, and resolve discrepancies before case lock. Continuous training and feedback loops further enhance accuracy.
What are the regulatory timelines for reporting a SUSAR in India and the United States?
In India, a SUSAR must be reported to CDSCO within 15 days of initial receipt. In the United States, the FDA requires a 7‑day report for fatal or life‑threatening SUSARs and a 15‑day report for other serious SUSARs. Adhering to these timelines is essential to avoid regulatory penalties.
Describe the role of MedDRA in pharmacovigilance.
MedDRA provides a standardized medical terminology for coding adverse events, facilitating consistent data analysis, signal detection, and regulatory reporting across regions. Accurate MedDRA coding improves data aggregation, enables comparative safety assessments, and supports global submissions.
How would you handle a case with incomplete information from a reporter?
I would initiate a follow‑up request promptly, specifying the missing data elements required for case completeness. I would document all communication attempts, use a structured query template, and, if necessary, involve the medical reviewer to prioritize the follow‑up based on seriousness.
What is a Periodic Safety Update Report (PSUR) and what information does it contain?
A PSUR is a comprehensive safety summary submitted at defined intervals (typically annually) that includes cumulative adverse event data, benefit‑risk evaluation, signal assessment, and updates to the risk management plan. It demonstrates ongoing safety monitoring for regulatory authorities.
Explain the difference between a serious and a non‑serious adverse event.
A serious adverse event results in death, is life‑threatening, requires hospitalization or prolongation of existing hospitalization, leads to persistent disability, or is a congenital anomaly. Non‑serious events do not meet these criteria but may still be clinically relevant.
How do you stay updated with changing global pharmacovigilance regulations?
I regularly review updates from regulatory agencies (FDA, EMA, CDSCO), attend industry webinars, subscribe to PV newsletters, and participate in professional networks. I also incorporate changes into SOPs and conduct internal training sessions to ensure compliance.
What steps would you take to prepare a safety narrative for a regulatory submission?
I would gather all relevant case details, assess causality, summarize clinical course, include MedDRA coding, and highlight any patterns or signals. The narrative would be concise, medically accurate, and aligned with regulatory guidelines, ensuring clarity for reviewers.
Describe how you would conduct a signal detection exercise using aggregated safety data.
I would extract aggregated case counts, apply disproportionality analysis (e.g., PRR, ROR), review temporal trends, and assess clinical relevance. Identified signals would be evaluated by a multidisciplinary team, documented, and, if warranted, communicated to health authorities.
What is the purpose of a Risk Management Plan (RMP) and how does a Drug Safety Associate contribute to it?
An RMP outlines strategies to identify, characterize, and minimize risks associated with a medicinal product. As a Drug Safety Associate, I provide safety data, signal assessments, and recommendations for risk minimization measures, ensuring the RMP remains evidence‑based and up‑to‑date.
How do you manage multiple case processing priorities under tight deadlines?
I prioritize based on seriousness, regulatory timelines, and impact on patient safety. I use a task‑tracking system, allocate dedicated time blocks, and communicate proactively with the team to ensure critical cases are completed first while maintaining overall workflow efficiency.
Explain the concept of de‑challenge and re‑challenge in adverse event assessment.
De‑challenge refers to the withdrawal of a suspect drug to observe if the adverse event resolves, while re‑challenge involves re‑introducing the drug to see if the event recurs. Positive de‑challenge/re‑challenge strengthens causality inference.
What documentation is required for an audit trail in pharmacovigilance?
An audit trail must capture who performed each action, timestamps, original source data, changes made, and justification for modifications. This ensures traceability, accountability, and compliance with regulatory expectations.
How would you handle a situation where a safety signal is identified for a product already on the market?
I would conduct a thorough signal evaluation, prepare a detailed assessment report, and recommend risk mitigation actions. The findings would be communicated to the safety lead, regulatory affairs, and, if required, reported to health authorities with an updated risk management plan.
What are the key elements of a good safety training program for new hires?
A comprehensive program includes regulatory overview, case processing workflow, database training (Argus), coding standards (MedDRA), SOP familiarization, hands‑on exercises, assessment quizzes, and ongoing mentorship to ensure competency.
Describe the process of preparing a Development Safety Update Report (DSUR).
The DSUR compiles cumulative safety data from clinical trials, includes a benefit‑risk evaluation, updates on ongoing studies, and incorporates any new safety signals. It follows ICH E2F guidelines and is submitted annually to regulatory agencies.
Loading latest jobs...